An international panel of the foremost researchers on infectious disease and antimicrobials has formed new guidelines on the use of polymyxins, a class of antibiotics employed as a last resort to treat deadly, drug-resistant bacteria.
The guidelines, published last month in Pharmacotherapy, set new standards for the clinical use of polymyxins, including on maximum dosage, treatment strategies and best practice for use in combination with other antibiotics.
“There is considerable confusion on how to optimally use the polymyxin antibiotics. These guidelines represent consensus recommendations from expert clinicians and scientists around the globe…”, said
Brian Tsuji, professor of pharmacy practice in the University at Buffalo School of Pharmacy and Pharmaceutical Sciences
Read more at University of Buffalo
- Temple mumps outbreak: 10 confirmed cases, 5 probable
- New York City to Boston bus trip and a traveler with measles
- Typhoid: Introduction of conjugate vaccine, progress and challenges
- Measles in Ukraine: Vaccination rate for newborn babies was only 54 per cent in 2018
- Nigeria reports 1st vaccine-derived poliovirus case of 2019
- Philippines Red Cross: 2.6 million children could be at risk for measles
- Tetanus: First pediatric case in >30 years in Oregon
- ‘We’re quickly getting to a scary place that’s called a post-antibiotic world’: Researchers
